Trials / Completed
CompletedNCT04943068
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 193 (actual)
- Sponsor
- Kwang Dong Pharmaceutical co., ltd. · Industry
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bremelanotide | Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector. |
| DRUG | Placebo | Subjects will self-administer a Placebo subcutaneously (SC) via auto-injector. |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2023-05-16
- Completion
- 2023-05-16
- First posted
- 2021-06-29
- Last updated
- 2024-11-13
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04943068. Inclusion in this directory is not an endorsement.